glp-1 shortage update Deepens in Two States as Demand Remains High GLP-1 Agonists Weight Loss Drugs

Genetic predispositions reveal individual differences in how the body's appetite and metabolic regulatory systems function at baseline

Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes

The statement made by the EMA said that its safety committee was currently evaluating the risk of suicidal thoughts and thoughts of self-harm in patients who used a semaglutide or liraglutide containing medicine for weight loss. The call for this evaluation is the result of three case reports: two cases of suicidal thoughts, one following the use of Saxenda (a daily liraglutide antidiabetic) and one following the use of Ozempic

Private-pay users need support after medication changes because NHS access may be limited and waiting times can be long

Investigational glucagon-like peptide-1 agonists for the treatment of obesity

Ozempic is mainly for type 2 diabetes but often used off-label for weight loss